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OAB because it eliminates the need for intradetrusor injection and allows for easy repetition of BoTN-A treatment.
BoTN-A treatment can be used for the management of chronic pelvic pain (CPP). It decreases pelvic pain by reducing pelvic muscle spasm, central and peripheral nerve sensitization, and noxious neurotransmitter release leading to reduction of neurogenic inflammation [5] . It has been recently reported that BoTN-A yields good results in treatment of interstitial cystitis or bladder pain syndrome, pelvic floor muscle pain, and chronic prostatitis or CPP syndrome.
However, some BoTN-A treatment results were not satisfactory. Early treatment result of BoTN-A for benign prostatic hyperplasia showed promise but the results from long-term follow-up were unsatisfactory. We expect BoTN-A to be a probable candidate for the management of CPP owing to the unavailability of appropriate treatment option for this disease thus far; however, long-term follow-up is required.
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